United Therapeutics Reports Record 2025 Financial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 25 2026
0mins
Should l Buy UTHR?
Source: Newsfilter
- Significant Revenue Growth: United Therapeutics achieved total revenues of $3.18 billion in 2025, marking an 11% increase year-over-year and setting a record for the fourth consecutive year, reflecting the company's ongoing commitment to innovation and excellence, which is expected to drive transformational growth ahead.
- Strong Tyvaso Sales: Sales of Tyvaso DPI grew by 25% to $1.29 billion in 2025, primarily due to a continued increase in patient numbers and enhanced commercial utilization following the redesign of the Medicare Part D benefit, further solidifying the company's market position.
- Increased R&D Investment: Research and development expenses reached $550 million in 2025, a 14% increase, indicating the company's sustained investment in manufactured organs and drug delivery technologies aimed at fostering future innovation and market competitiveness.
- Share Repurchase Program: United Therapeutics repurchased approximately $1 billion of its stock in 2025 through accelerated share repurchase agreements, demonstrating confidence in its value while also creating long-term value for shareholders.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy UTHR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on UTHR
Wall Street analysts forecast UTHR stock price to rise
8 Analyst Rating
5 Buy
3 Hold
0 Sell
Moderate Buy
Current: 498.650
Low
423.00
Averages
534.50
High
645.00
Current: 498.650
Low
423.00
Averages
534.50
High
645.00
About UTHR
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ralinepag Phase 3 Study Achieves Key Endpoints
- Clinical Trial Success: The ADVANCE OUTCOMES study demonstrated that ralinepag met its primary endpoint by reducing the risk of clinical worsening by 55%, indicating its potential to redefine treatment for pulmonary arterial hypertension (PAH) patients.
- Significant Efficacy: Ralinepag increased the odds of clinical improvement by 47% and showed statistically significant improvements in key secondary endpoints such as six-minute walk distance and NT-proBNP, reinforcing its consistent efficacy across various patient subgroups.
- FDA Submission Plans: United Therapeutics intends to submit a New Drug Application (NDA) for ralinepag to the FDA by the second half of 2026, which could provide new treatment options for PAH patients and address the urgent market demand for innovative therapies.
- Good Safety Profile: Ralinepag was well-tolerated, with a safety profile consistent with known prostacyclin-related adverse events, and no new safety signals were observed, enhancing its appeal as a long-term treatment option.
See More
United Therapeutics Drug Clinical Trial Success
- Clinical Trial Milestone: United Therapeutics announced that its drug ralinepag achieved its primary endpoint in the phase 3 ADVANCE OUTCOMES study, demonstrating a 55% reduction in the risk of clinical worsening events in patients with pulmonary arterial hypertension, laying a solid foundation for future market performance.
- Improvement Odds: The study results indicated a 47% increase in the odds of clinical improvement in predominantly pre-treated patients, with plans to submit a New Drug Application (NDA) to the FDA by the second half of 2026, further advancing the company's strategic positioning in the cardiopulmonary disease sector.
- Safety Validation: Ralinepag was well-tolerated in the trial, with no new safety signals observed, enhancing its potential as a transformative treatment for pulmonary arterial hypertension, which may attract more investor interest.
- Market Performance Analysis: Despite broader market declines, United Therapeutics' stock rose by 3.98%, indicating a positive impact from company-specific news, with the current stock price at $503.90, close to its 52-week high, reflecting a strong long-term trend.
See More
United Therapeutics Achieves Breakthrough in Drug Study
- Clinical Trial Success: United Therapeutics' long-term Phase 3 ADVANCE OUTCOMES study of ralinepag in pulmonary arterial hypertension met its primary endpoint, reducing the risk of clinical worsening by 55% compared to placebo, indicating significant efficacy and potential new treatment options for patients.
- Patient Background Analysis: Among the trial participants, 80% were on dual background therapy and 70% were classified as World Health Organization/New York Heart Association Functional Class II at baseline, suggesting the drug's applicability across various stages of the disease and enhancing its market potential.
- Future Plans: The company intends to submit a New Drug Application to the U.S. Food and Drug Administration in the second half of 2026, which, if approved, would provide a new treatment option for pulmonary arterial hypertension patients and further expand its product line.
- Market Reaction: United Therapeutics' shares closed at $503.90 on Friday, up 0.06%, reflecting market optimism regarding the progress of its drug development, which may drive future stock performance.
See More
United Therapeutics Reports Strong Q4 Earnings Exceeding Expectations
- Earnings Beat: United Therapeutics reported Q4 earnings of $7.70 per share, surpassing analyst expectations of $7.09, indicating strong profitability despite sales falling short of forecasts.
- Sales Miss: The company recorded quarterly sales of $790.2 million, which was below the consensus estimate of $813.077 million, reflecting potential fluctuations in market demand impacting revenue growth.
- Positive Outlook: CEO Martine Rothblatt, Ph.D., highlighted that the ADVANCE OUTCOMES and TETON-1 clinical programs are on the verge of releasing pivotal data, which could unlock significant new treatment options for patients and signal a period of transformational growth for the company.
- Stock Reaction: Despite the earnings beat, United Therapeutics shares fell 5.6% to $505.28 on Thursday, indicating market concerns over the sales miss and its implications for future performance.
See More
United Therapeutics' New Drug Plans Pressure Partner and Rival Stocks
- New Drug Launch Plans: United Therapeutics (UTHR) announced plans to launch a new drug device formulation of its lung therapy treprostinil next year, which led to a ~38% drop in partner MannKind (MNKD) shares and a ~10% decline in rival Liquidia (LQDA) shares.
- Market Reaction: The significant stock declines of MannKind and Liquidia reflect strong market interest in United's new product, Tresmi, designed to reduce the primary side effect of dry powder inhalers—coughing—by up to 90% based on preliminary human studies.
- Patent Litigation Context: Despite ongoing patent litigation with United, Liquidia plans to launch its dry powder formulation Yutrepia in 2025, intensifying market competition and potentially impacting MannKind's market share.
- FDA Filing Plans: United Therapeutics expects to file for FDA approval for PAH and PH-ILD this year, with CEO Martine Rothblatt stating that the new product will change patient reliance on treatments and reduce discontinuation due to cough.
See More
MannKind Faces Uncertainty Over Tyvaso DPI Royalties
- New Product Impact: United Therapeutics' launch of Tresmi, which could replace Tyvaso DPI, introduces uncertainty for MannKind regarding long-term royalty revenues, as evidenced by a 38% drop in MannKind's stock on Wednesday, reflecting market concerns about future income.
- Market Reaction: Despite the significant selloff, H.C. Wainwright analyst noted that the decline may underestimate the potential value of the DPI formulation in the long term, maintaining a ‘Buy’ rating with an $11 price target on MannKind shares.
- Revenue Growth: MannKind reported a 26% revenue increase in the first nine months of 2025, primarily attributed to rising royalties from Tyvaso DPI, underscoring the product's significance in the market.
- User Sentiment Shift: On Stocktwits, retail sentiment around MannKind and United Therapeutics shifted from ‘bearish’ to ‘bullish’ in the past 24 hours, indicating a more optimistic outlook among investors regarding future developments.
See More
Ralinepag Phase 3 Study Achieves Key Endpoints
- Clinical Trial Success: The ADVANCE OUTCOMES study demonstrated that ralinepag met its primary endpoint by reducing the risk of clinical worsening by 55%, indicating its potential to redefine treatment for pulmonary arterial hypertension (PAH) patients.
- Significant Efficacy: Ralinepag increased the odds of clinical improvement by 47% and showed statistically significant improvements in key secondary endpoints such as six-minute walk distance and NT-proBNP, reinforcing its consistent efficacy across various patient subgroups.
- FDA Submission Plans: United Therapeutics intends to submit a New Drug Application (NDA) for ralinepag to the FDA by the second half of 2026, which could provide new treatment options for PAH patients and address the urgent market demand for innovative therapies.
- Good Safety Profile: Ralinepag was well-tolerated, with a safety profile consistent with known prostacyclin-related adverse events, and no new safety signals were observed, enhancing its appeal as a long-term treatment option.
See More
United Therapeutics Drug Clinical Trial Success
- Clinical Trial Milestone: United Therapeutics announced that its drug ralinepag achieved its primary endpoint in the phase 3 ADVANCE OUTCOMES study, demonstrating a 55% reduction in the risk of clinical worsening events in patients with pulmonary arterial hypertension, laying a solid foundation for future market performance.
- Improvement Odds: The study results indicated a 47% increase in the odds of clinical improvement in predominantly pre-treated patients, with plans to submit a New Drug Application (NDA) to the FDA by the second half of 2026, further advancing the company's strategic positioning in the cardiopulmonary disease sector.
- Safety Validation: Ralinepag was well-tolerated in the trial, with no new safety signals observed, enhancing its potential as a transformative treatment for pulmonary arterial hypertension, which may attract more investor interest.
- Market Performance Analysis: Despite broader market declines, United Therapeutics' stock rose by 3.98%, indicating a positive impact from company-specific news, with the current stock price at $503.90, close to its 52-week high, reflecting a strong long-term trend.
See More
United Therapeutics Achieves Breakthrough in Drug Study
- Clinical Trial Success: United Therapeutics' long-term Phase 3 ADVANCE OUTCOMES study of ralinepag in pulmonary arterial hypertension met its primary endpoint, reducing the risk of clinical worsening by 55% compared to placebo, indicating significant efficacy and potential new treatment options for patients.
- Patient Background Analysis: Among the trial participants, 80% were on dual background therapy and 70% were classified as World Health Organization/New York Heart Association Functional Class II at baseline, suggesting the drug's applicability across various stages of the disease and enhancing its market potential.
- Future Plans: The company intends to submit a New Drug Application to the U.S. Food and Drug Administration in the second half of 2026, which, if approved, would provide a new treatment option for pulmonary arterial hypertension patients and further expand its product line.
- Market Reaction: United Therapeutics' shares closed at $503.90 on Friday, up 0.06%, reflecting market optimism regarding the progress of its drug development, which may drive future stock performance.
See More
United Therapeutics Reports Strong Q4 Earnings Exceeding Expectations
- Earnings Beat: United Therapeutics reported Q4 earnings of $7.70 per share, surpassing analyst expectations of $7.09, indicating strong profitability despite sales falling short of forecasts.
- Sales Miss: The company recorded quarterly sales of $790.2 million, which was below the consensus estimate of $813.077 million, reflecting potential fluctuations in market demand impacting revenue growth.
- Positive Outlook: CEO Martine Rothblatt, Ph.D., highlighted that the ADVANCE OUTCOMES and TETON-1 clinical programs are on the verge of releasing pivotal data, which could unlock significant new treatment options for patients and signal a period of transformational growth for the company.
- Stock Reaction: Despite the earnings beat, United Therapeutics shares fell 5.6% to $505.28 on Thursday, indicating market concerns over the sales miss and its implications for future performance.
See More
United Therapeutics' New Drug Plans Pressure Partner and Rival Stocks
- New Drug Launch Plans: United Therapeutics (UTHR) announced plans to launch a new drug device formulation of its lung therapy treprostinil next year, which led to a ~38% drop in partner MannKind (MNKD) shares and a ~10% decline in rival Liquidia (LQDA) shares.
- Market Reaction: The significant stock declines of MannKind and Liquidia reflect strong market interest in United's new product, Tresmi, designed to reduce the primary side effect of dry powder inhalers—coughing—by up to 90% based on preliminary human studies.
- Patent Litigation Context: Despite ongoing patent litigation with United, Liquidia plans to launch its dry powder formulation Yutrepia in 2025, intensifying market competition and potentially impacting MannKind's market share.
- FDA Filing Plans: United Therapeutics expects to file for FDA approval for PAH and PH-ILD this year, with CEO Martine Rothblatt stating that the new product will change patient reliance on treatments and reduce discontinuation due to cough.
See More
MannKind Faces Uncertainty Over Tyvaso DPI Royalties
- New Product Impact: United Therapeutics' launch of Tresmi, which could replace Tyvaso DPI, introduces uncertainty for MannKind regarding long-term royalty revenues, as evidenced by a 38% drop in MannKind's stock on Wednesday, reflecting market concerns about future income.
- Market Reaction: Despite the significant selloff, H.C. Wainwright analyst noted that the decline may underestimate the potential value of the DPI formulation in the long term, maintaining a ‘Buy’ rating with an $11 price target on MannKind shares.
- Revenue Growth: MannKind reported a 26% revenue increase in the first nine months of 2025, primarily attributed to rising royalties from Tyvaso DPI, underscoring the product's significance in the market.
- User Sentiment Shift: On Stocktwits, retail sentiment around MannKind and United Therapeutics shifted from ‘bearish’ to ‘bullish’ in the past 24 hours, indicating a more optimistic outlook among investors regarding future developments.
See More
